Departments / Psychiatry and Behavioral Neuroscience / Research / Clinical Research / Center for Addiction Research / Ohio Valley Node-Network

Ohio Valley Node

The Ohio Valley Node (OVN) joined the Clinical Trials Network in September 2000. The OVN includes successful partnerships with four healthcare systems, two pharmacy networks, and six addiction specialty/ infectious disease programs. These collaborating sites span a seven-state region including some of the states most heavily impacted by opioid (Ohio, Kentucky, and West Virginia) and methamphetamine (Missouri, Kentucky, and North Dakota) use. The OVN includes Midwestern, Appalachian, Upper South, and Native American representation, which significantly enhances the geographical and cultural diversity of the CTN. The OVN has an outstanding history of successful participation in CTN clinical trials: 15 OVN sites, located in seven different states, have served in >30 CTN trials. Completed trials are listed below.

See completed list of Projects

CTN-0001Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification
CTN-0002Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification
CTN-0008Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation
CTN-0012Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
CTN-0013Motivational Enhancement Therapy to Improve Treatment Utilization and Outcome in Pregnant Substance Users
CTN-0014Brief Strategic Family Therapy for Adolescent Drug Abusers
CTN-0014-A-1Mediators and Moderators of Brief Strategic Family Therapy (BSFT) for Adolescent Drug Use
CTN-0015Women's Treatment for Trauma and Substance Use Disorders
CTN-0018Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment
CTN-0019Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment
CTN-0028Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents (with Substance Use Disorder)
CTN-0029Attention Deficit Hyperactivity Disorder (ADHD) in Adult Smokers
CTN-0030Prescription Opioid Addiction Treatment Study (POATS)
CTN-0030-A-1Collection of Economic Data for the Prescription Opioid Addiction Treatment Study
CTN-0031Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement
CTN-0031-A-1An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association with Treatment Outcomes in Methamphetamine and Cocaine Abusers
CTN-0032HIV Rapid Testing and Counseling
CTN-0032-A-1Economic Analysis of HIV Rapid Testing in Drug Abuse Treatment Programs
CTN-0033-Ot-4An Exploration of Methamphetamine and Other Drug Use and Treatment Options Among Urban and Rural Northern Plains American Indians
CTN-0037Stimulant Reduction Intervention Using Dosed Exercise (STRIDE)
CTN-0037-A-1Site Influences on Treatment Effects - Exercise as a Treatment for Substance Use Disorders
CTN-0042-SEfficacy of Motivational Enhancement Therapy for African Americans
CTN-0044Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
CTN-0044-A-2Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native
CTN-0046Smoking Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking Cessation and Stimulant Treatment on Stimulant Dependence
CTN-0047Screening Motivational Assessment and Referral to Treatment in Emergency Departments (SMART-ED): Evaluation of Screening, Brief Intervention, Referral to Treatment (SBIRT) and Booster Session for Drug Use Patients Presenting for Treatment in the Emergency Department
CTN-0048Cocaine Use Reduction with Buprenorphine (CURB)
CTN-0049Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users (Project HOPE)
CTN-0051Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)
CTN-0051-A-1Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) Genetics Study
CTN-0051-A-2Treatment-As-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with CTN-0051
CTN-0052Buspirone for Relapse Prevention in Adults with Cocaine Dependence (BRAC)
CTN-0053Achieving Cannabis Cessation -- Evaluating N-Acetylcystein Treatment (ACCENT)
CTN-0055Comparing Treatments for HIV-Positive Opioid Users in an Integrated Care Effectiveness Study (CHOICES)
CTN-0064Linkage to Hepatitis C Virus (HCV) Care among HIV/HCV Co-infected Substance Users

More Infomation

Addiction Sciences Division

Department of Psychiatry & Behavioral Neuroscience
3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229

Frankie Kropp: 513-585-8290

Directory Search
Intranet Login

Contact Us

Department of
Psychiatry and Behavioral Neuroscience

Stetson Building Suite 3200
260 Stetson Street
PO Box 670559
Cincinnati, OH 45267-0559